<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) is accepted as a therapy for leukaemic diseases and varying inborn diseases if a suitable related donor cannot be found </plain></SENT>
<SENT sid="1" pm="."><plain>The goal of immunosuppressive therapy with UD-HSCT is an effective prevention of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> (GvHD) on one hand </plain></SENT>
<SENT sid="2" pm="."><plain>On the other hand an optimal balance with immunocompetence of the transplanted bone marrow is desirable in order to prevent graft failure, <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and, in the case of leukaemic diseases, potentially control the underlying disease </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Between 1992 and 2000 49 patients aged 11 months to 16.7 years received an UD-HSCT in Hamburg </plain></SENT>
<SENT sid="4" pm="."><plain>Underlying diseases were <z:mpath ids='MPATH_336'>leukaemia</z:mpath> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in 35, of these ALL in 21, <z:e sem="disease" ids="C0024291" disease_type="Disease or Syndrome" abbrv="">hemophagocytic lymphohistiocytosis</z:e> (HLH) in 9, <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> or <z:e sem="disease" ids="C0025521" disease_type="Disease or Syndrome" abbrv="">inborn error of metabolism</z:e> in 5 patients </plain></SENT>
<SENT sid="5" pm="."><plain>GvHD-prophylaxis consisted of a combination of <z:chebi fb="0" ids="4031">Cyclosporin A</z:chebi> (CSA), <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX), <z:chebi fb="1" ids="6909">metronidazole</z:chebi>, IgM-enriched iv-immunoglobulin (ivIg) (Pentaglobin(R)) or ivIgG and anti-thymocyte-globulin (ATG) </plain></SENT>
<SENT sid="6" pm="."><plain>Within the same time span 10 patients with ALL received a matched related donor HSCT (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>-HSCT) </plain></SENT>
<SENT sid="7" pm="."><plain>GvHD-prophylaxis in these patients was done without ATG in 8 of 10 cases </plain></SENT>
<SENT sid="8" pm="."><plain>UD-HSCT were analyzed for survival, relapse and toxicity </plain></SENT>
<SENT sid="9" pm="."><plain>Probability of survival of the patients with ALL after UD-HSCT was compared with results of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>-HSCT in children with ALL </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: The Kaplan-Meier estimates of three year overall-survival (OS) were 74 % for <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="11" pm="."><plain>Probability of disease-free survival (DFS) at three years was 62 % for <z:mpath ids='MPATH_336'>leukaemia</z:mpath>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-patients and 100 % for the HLH-patients </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GvHD (aGvHD) grades II or III occurred in 51 % of patients </plain></SENT>
<SENT sid="13" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GvHD (cGvHD) occurred in 22 % of patients </plain></SENT>
<SENT sid="14" pm="."><plain>There were 5 cases of treatment-related mortality (TRM) </plain></SENT>
<SENT sid="15" pm="."><plain>Probability of DFS for patients with ALL at three years was 65 % after UD-HSCT and 30 % in the patients after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>-HSCT </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSIONS: UD-HSCT in children is an effective and safe therapy </plain></SENT>
<SENT sid="17" pm="."><plain>A GvHD-prophylaxis regimen combining the standard <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> CSA and MTX with ivIg, <z:chebi fb="1" ids="6909">metronidazole</z:chebi> and serotherapy using ATG may result in a low incidence of severe GvHD-complications and low TRM rate without increase in relapse rates </plain></SENT>
</text></document>